Abcam acquires Expedeon's Proteomics and Immunology business

Abcam, a global innovator in life science reagents and tools, has announced the successful completion of the acquisition of Expedeon’s Proteomics and Immunology business, which includes Innova Biosciences and TGR BioSciences, as of 1 January 2020. Abcam and Expedeon say they are fully committed to providing continued access to Expedeon’s proteomics and immunology products and support so that the life science community can perform their research and development without interruption.

Proteomics research requires the use of molecular labels that are covalently attached to a protein of interest to facilitate detection or purification of the protein or its binding partners. With conjugation kits for over 50 types of labels for applications across the life science industry, Expedeon’s technology supports a diverse set of labels, including enzymes, metals, oligos and fluorescent proteins. Abcam will combine the newly acquired capture and conjugation technologies with its extensive antibody and protein expertise to expand and enhance its portfolio of off-the-shelf and custom reagents and tools.

The news comes two months after Abcam announced a strategic partnership with BrickBio, a biotech company specialising in site-specific protein modification, covering the use of the latter’s proprietary platform for introducing conjugation-ready sites into antibodies and other proteins in both mammalian and bacterial expression systems.

“Our reputation as an innovator in the field of biological reagents, coupled with our dedicated global commercialisation infrastructure, will allow us to make these technologies readily available globally,” said Dr John Baker, SVP Product Portfolio and Innovation, Abcam.

“We have had teams working on conjugation for several years and the combination of this expertise with the Expedeon portfolio and other complementary conjugation technologies, including BrickBio’s, provides a very powerful platform to enable us to deliver the precision research tools required to address the majority of life science assays used today and those emerging in the future.”

Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.